Greer to Present Findings of Sublingual-Oral Immunotherapy Safety and Dosing Trials at 2006 American Academy of Allergy Asthma and Immunology Meeting.

LENOIR, N.C. -- Greer, a leading developer and provider of allergy immunotherapy products and treatments, will present findings of its recently completed Phase I safety and dosing trials for sublingual-oral immunotherapy at the American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting March 3-7 at the Miami Beach Conference Center in Miami Beach, Fla.

Sublingual-oral immunotherapy is administered under the tongue and in many countries is a popular method for delivering allergy immunotherapy. Though widely used in Europe, there are currently no FDA approved products for sublingual immunotherapy in the United States. Greer recently completed safety and dosing trials for the sublingual administration of standardized dust mite, ragweed, Timothy grass and cat hair extracts.

During the trials, more than 4,500 doses of sublingual-oral immunotherapy were administered during an eight-week period to nearly 100 adult participants. Approximately 30 percent of study participants had asthma. Side effects were generally mild to moderate and included oral mucosal itching and irritation; itchy, runny stuffy nose, and irritation of the eyes, which were self-resolving or subsided after dose adjustment.

"We are pleased with the results of our safety and dosing trials," says Dr. Bob Esch, Greer's executive vice president of research and development. "Until now, virtually all of the controlled studies supporting the safety and effectiveness of sublingual-oral immunotherapy have been conducted in Europe and Canada. Our trials were designed to evaluate a safe dosing regimen for sublingual immunotherapy, which is what the U.S. medical community has been waiting for."

Additional details on Greer's sublingual-oral immunotherapy safety and dosing trials will be available at the AAAAI meeting. Greer will begin Phase III parallel, randomized double-blind placebo controlled trials to further establish the safety and efficacy of sublingual-oral immunotherapy later this year.

About Greer: Greer is a leading developer and provider of allergy immunotherapy products and services for treating humans and animals. Greer's highly skilled scientists provide technical support for customers by continuing to focus on improving the lives of allergic patients. The company was founded in 1904 and is located in Lenoir, N.C. To learn more about Greer, visit us at www.greerlabs.com.